Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.
Andrew Brenner, MD, PhD
Advertisement
Andrew Brenner, MD, PhD, is a breast and neuro-oncology specialist and professor of medicine in the Division of Hematology and Oncology at the University of Texas Health Science Center at San Antonio.
Articles by Andrew Brenner, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
5
